Tyfill Pharmapack Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 13-12-2024
- Paid Up Capital ₹ 0.50 M
as on 13-12-2024
- Company Age 18 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2021)
- Profit 52.01%
(FY 2021)
- Ebitda 96.20%
(FY 2021)
- Net Worth -3.20%
(FY 2021)
- Total Assets
About Tyfill Pharmapack
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Harsh Shandilya, Champa Narottam, and Harsha Mulani serve as directors at the Company.
- CIN/LLPIN
U24230MH2006PLC160043
- Company No.
160043
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
15 Feb 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Tyfill Pharmapack Limited offer?
Tyfill Pharmapack Limited offers a wide range of products and services, including Industrial & Engineering Goods, Precision Rods, Scalpels, Needles & Scissors, Surgical Needles.
Who are the key members and board of directors at Tyfill Pharmapack?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Harsh Shandilya  | Director | 15-Feb-2006 | Current |
| Champa Narottam | Director | 15-Feb-2006 | Current |
| Harsha Mulani | Director | 15-Feb-2006 | Current |
Financial Performance of Tyfill Pharmapack.
Tyfill Pharmapack Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 52.01% increase in profit. The company's net worth dipped by a decrease of 3.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tyfill Pharmapack?
In 2022, Tyfill Pharmapack had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Top Syringe Manufacturing Company Private LimitedActive 13 years 9 monthsHarsh Shandilya is a mutual person
- Sunderji Chatrabhuj Estates Private LimitedActive 14 years 9 months
Harsh Shandilya is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Tyfill Pharmapack?
Unlock and access historical data on people associated with Tyfill Pharmapack, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tyfill Pharmapack, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tyfill Pharmapack's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
